<i>Lactobacillus gallinarum</i>-derived metabolites boost anti-PD1 efficacy in colorectal cancer by inhibiting regulatory T cells through modulating IDO1/Kyn/AHR axis

Abstract

<i>L. gallinarum</i>-derived ICA improved anti-PD1 efficacy in CRC through suppressing CD4+Treg differentiation and enhancing CD8+T cell function by modulating the IDO1/Kyn/AHR axis. <i>L. gallinarum</i> is a potential adjuvant to augment anti-PD1 efficacy against CRC.